Physician profile
Daniel A Boccardo
NPI 1568422913
$2,428.04
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $544 · 2021: $578 · 2022: $355 · 2023: $29.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $376.22 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $371.71 | 2019-2021 | |
| Novo Nordisk INC | $369.50 | 2019-2022 | |
| Lilly USA, LLC | $309.01 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $194.39 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $129.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $120.26 | 2019-2021 | |
| Amgen INC. | $118.44 | 2020-2021 | |
| Astellas Pharma US INC | $106.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $96.05 | 2022-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $59.68 | 2019 | |
| Pfizer INC. | $41.77 | 2019-2021 | |
| Biotronik INC. | $40.99 | 2019 | |
| Bardy Diagnostics, INC. | $32.00 | 2020-2021 | |
| Cumberland Pharmaceuticals, INC. | $31.72 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.48 | 2020 | |
| Medtronic Vascular, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Boccardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.